Displaying 1–25 of 101 results for Karen Langhauser, Chief Content Director
Pharma's gene therapy dreams need to be tethered with a plan
The definition of pharma innovation isn’t always clear cut
Pharma Manufacturing's annual Pharma Innovation Award winners offer slices of innovation
Shared pursuits might lead to bigger rewards
The buzz may be around biologics, but the oral solid dose sector is still going strong
INTERPHEX 2019 conference recap
For pharma, it pays to update facilities and mindsets
Reaching new frontiers will require both strategic and financial planning
Pharma navigates unfriendly terrain to reach the next frontier in affordable drugs
Despite negative public opinions and heavy demands, survey respondents indicate rising satisfaction and pride in their work
Can the pharma industry restore luster to its dimming reputation?
AAM Access! 2019 makes it clear that generics have earned their seat at the table
Pharma CMOs are sharpening their arrows and getting noticed
iBio’s unique partnership with Beijing’s CC-Pharming will bring economical, plant-derived rituximab to China
China-based Porton Pharma’s partnership with Codexis will bring new and improved manufacturing routes for APIs
This year, pharma regulators faced their own music
As Pharmaceutical Manufacturing sends its final issue of 2018 to the printer, we’d like to take this opportunity to reflect on some of our favorite highlights:
Premature promises about cell therapies create expectations ripe for disappointment
Can unproven therapies spoil the sector’s sweet success?
Why pharma needs to kick open the closet and confront its digital demons
To advance, the pharma industry must confront its digital transformation fears head-on
Pharma needs to kick open the closet and confront its digital demons
If self-reliance wasn’t typical of the puerto rican pharma industry previously, it is now. Rather than complaining about the wind, pharma adjusts its sails.
One year after Hurricane Maria, Puerto Rico's pharma industry is standing its ground. The post-Maria effort from the pharmaceutical industry, like that of Puerto Rico as a whole, is a story about resilience.